Talk to an Expert

Actionable Tissue Intelligence

for ADC Clinical Development

Turn tissue into evidence that answers why your ADC works, and which patients benefit. Achieve sharper patient selection, de-risk trials, and inform CDx strategy.

Nucleai's tissue intelligence platform pairs multimodal analysis of H&E and IHC images with outcomes linkage, extracting the target expression, tissue architecture, and microenvironmental context that explain ADC response, resistance, and survival. The result is actionable intelligence to build program decisions on.

Talk to an Expert
Partnership

Nucleai and Gilead Sciences:
tissue intelligence in ADC development

An ongoing translational research collaboration supporting Gilead's global ADC clinical development programs, analyzing H&E and IHC whole-slide images across several clinical studies and multiple oncology indications, integrated with clinical outcomes data.
Learn More
The Challenge

In ADC development, two questions decide a program's path: why does it work, and which patients will benefit?

Both answers live in the tissue, but they're hard to reach.

Complex biology hidden in plain sight

Target heterogeneity, influence of fibrosis, inflammation and vascularity in the microenvironment are all missed by a single expression score.

Standard methods miss the full context

% positivity and H-scores give the headline, but don't read the entire page. This misses spatial context and patient-to-patient variation.

The cost shoes up downstream

When tissue biology is oversimplified, the consequences can include missed responders, diluted efficacy signals, broader patient enrollment, and more difficult biomarker and CDx decisions.

Nucleai's Solution

Tissue Intelligence Built for ADC Development

Nucleai's tissue intelligence platform, delivered as expert-led analysis, pairs capabilities that rarely come together:

Multimodal tissue analysis

Extract structured, reproducible spatial features from H&E and IHC, capturing subcellular target expression, tissue architecture, heterogeneity, and tumor-immune context at cohort scale.

Outcomes linkage

Systematically test tissue features and thresholds against clinical outcomes to identify patterns associated with response, resistance, and survival. Analysis can also run within the sponsor environment.

Traceable output

Trace every finding back to the source image, with pathologist and scientific review supporting biological interpretation and reproducibility.

Built for

clinical confidence and scale:

  • Multimodal depth
  • Specialized foundation model with expert-supervised grounding
  • Multiple clinical studies across a global ADC program
  • Proven delivery across 30+ clinical trials and 10+ indications
Our models adapt to your data, generating structured tissue intelligence designed to hold up across independent patient cohorts.
Track Record

30+

Clinical trials

10+

Indications

12+

of top 20 biopharma supported

Multiple drug classes

Including ADCs

Large datasets of H&E and IHC whole-slide images

Multiple clinical studies across a global ADC program

Multiple oncology indications

Integration with clinical outcomes data

Ready to Advance Your ADC Biomarker Strategy?

Whether you're exploring new biomarkers, sharpening patient selection, or preparing for companion diagnostic development, our team can help you find the actionable intelligence your tissue already holds.
Read the latest oncology ADC collaboration news